Heron Therapeutics Falls 11%, Company Says FDA Has Not Concluded A Scheduled Review


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Heron Therapeutics Inc (NASDAQ: HRTX) announced on Monday that the U.S. Food and Drug Administration (FDA) has not taken any action on its New Drug Application (NDA) for SUSTOL.

The FDA informed Heron Therapeutics that it has not yet concluded a review of the NDA despite a January 17, 2016, deadline expected late February.

Shares of Heron Therapeutics were trading lower by more than 4 percent shortly after Monday's market open, and have since continued to drop.

Heron Therapeutics added that the FDA could not yet provide an anticipated action date but will communicate a new action date later on this week.

At the time of this publication, heron was trading down 11.53 percent on the day at $16.57.


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsShort IdeasFDAMoversTrading IdeasGeneralHeron TherapeuticsNew Drug ApplicationSUSTOL